Mostrar Notícias:

BMYPrincipaisÚltima HoraBovespa - Brasil

Pesquisa de notícias relativas à acção BRISTOL MYERS SQI (ordenadas pela data):

GlaxoSmithKline Buys Unit From Bristol Myers-Squibb Zawya LN) Thursday said it bought another Middle East generics business from Bristol-Myers Squibb Co. (BMY)Bristol-Myers Squibb Co. (BMY), once again furthering ... GlaxoSmithKline Acquires Branded Generics Business Of Bristol ...RTT News Glaxo buys Bristol generic drugs in MideastReuters India all 31 news articles »

Proactive Investors UK

Astra, Bristol diabetes drug recommended in Europe Reuters L) and Bristol-Myers Squibb Co (BMY.N), clearing the way for its launch in the coming months. Recommendations from the European Medicines Agency are ... Bristol diabetes drug gets positive EU reviewBusinessWeek STOCKS NEWS EUROPE-AstraZeneca up on EU diabetes drug newsReuters UK AstraZeneca: ONGLYZA Receives Positive Opinion From CHMPWall Street Journal The News Journal -Trading Markets (press release) -Hays Pharma -Investors Chronicle all 51 news articles »

AZZ, Bristol-Myers Squibb, Epoch Holding: US Equity Movers Bloomberg Bristol-Myers Squibb Co. (BMY US) fell 1.9 percent to $20.57, the steepest decline since June 15. The New York-based global biopharmaceutical was cut to ... and more »

Bristol Myers (BMY) PriceWatch Alert Up To 5.65% Downside Protection Market Intelligence Center Bristol Myers (NYSE: BMY) closed yesterday at $20.19. So far the stock has hit a 52-week low of $16.00 and 52-week high of $23.98. Bristol Myers stock has ... and more »

Adding to Two Defensive Plays TheStreet.com (subscription) After you have received this Alert, I am going to buy 300 shares of Bristol-Myers Squibb (BMY:NYSE) at $19.74 and 900 shares of Altria (MO:NYSE) at $16.27. ... and more »

Bristol Myers (BMY) PriceWatch Alert Down To $18.12 Break Even Market Intelligence Center Bristol Myers (NYSE: BMY) closed yesterday at $19.38. So far the stock has hit a 52-week low of $16.00 and 52-week high of $23.98. Bristol Myers stock has ... Bristol Myers (BMY) NewsBite - BMY Rises on Analyst's CommentsMarket Intelligence Center all 2 news articles »

Examiner.com

Wichita physician and medical resident Melissa Chenoweth receives ... Examiner.com Wichita physician Dr. Melissa Chenoweth received the prestigious Bristol Myers Squibb award for excellence in graduate medical education. ... and more »

Obama-Proof: Pfizer, Bristol-Myers and Teva TheStreet.com Pfizer(PFE Quote), Bristol-Myers Squibb(BMY Quote) and Teva Pharmaceuticals(TEVA Quote) are three of them. Recommended as "buy" by TheStreet.com Ratings, ... and more »

Marshalling Evidence for What Makes Sense in Health Care Barron's Those biotech treatments include Humira from Abbott Laboratories (ABT), Remicade from Johnson & Johnson (JNJ) and Orencia from Bristol-Myers Squibb (BMY). ... and more »

Back to Defensives TheStreet.com (subscription) I like the ones with the high yields -- I'm anxious to buy some Altria (MO - commentary - Trade Now) and Bristol Myers (BMY - commentary - Trade Now), ... and more »

Marketing Magazine

Bristol-Myers Squibb Picks MediaVest MediaPost Publications Bristol-Myers Squibb has awarded its estimated $420 million media assignment to MediaVest after a review. Through the first four months of this year, ... MediaVest Wins $400 Million Bristol-Myers Squibb AccountAdAge.com (subscription) Bristol-Myers Squibb Picks MediaVestBrandweek Magazine Bristol-Myers Squibb gets racyMedia In Canada all 6 news articles »

Bristol-Myers Squibb change distribution arrangements Dispensing Doctors' Association Bristol-Myers Squibb Pharmaceuticals (including Mead Johnson Nutritionals) has announced that it will use just two wholesalers for most of its products from ... Bristol-Myers Squibb selects AAH and Alliance Healthcare as ...Chemist+Druggist all 2 news articles »

Results from Bristol Myers' (BMY), AstraZeneca's (AZN ... StreetInsider.com (subscription) Dapagliflozin is an investigational SGLT2 inhibitor currently in Phase 3 trials under joint development by Bristol-Myers Squibb Company (NYSE: BMY) and ... and more »

Deals of the day -- mergers and acquisitions Reuters L) expanded its emerging markets footprint by buying Bristol-Myers Squibb's (BMY.N) branded generics drugs business in Lebanon, Jordan, Syria, ... and more »

Onglyza Gets Thumbs Up in Europe for the Treatment of Type 2 Diabetes Trading Markets (press release) Jun 30, 2009 (Close-Up Media via COMTEX) -- BMY | Quote | Chart | News | PowerRating -- Bristol-Myers Squibb Company and AstraZeneca announced that their ... CHMP positive opinion for saxagliptinPharmacy Europe all 3 news articles »

Weekly Roundup TheStreet.com (subscription) Bristol-Myers Squibb (BMY:NYSE, $19.77, 3000 shares, 2.42%): Positive primary results on Bristol-Myers' pain drug apixaban were released this week that ... and more »

The Star-Ledger - NJ.com

Bristol-Myers shares look attractive WallStNation.com Bristol Myers Squibb Co. (NYSE:BMY) shares are down in the $19 range and down 3% in the last month. Bristol-Myers Squibb is a moderate-risk stock at this ... Bristol-Myers Squibb supports HomeFront in effort to help families ...The Star-Ledger - NJ.com Bristol-Myers Squibb declares USD0.31 common and USD0.50 preferred ...Trading Markets (press release) Bristol Myers (BMY) PriceWatch Alert Targets 6.94% Downside ProtectionMarket Intelligence Center PharmiWeb.com (press release) -PR-Inside.com (Pressemitteilung) -Trading Markets (press release) all 15 news articles »

French and Benelux stocks - Factors to watch on July 1 Forbes The French advertising group has won a contract from US drugmaker Bristol-Myers Squibb ( BMY - news - people ) US trade magazine Adweek said. ... and more »

Bristol, Elan Antibiotic Not Linked to Risk of Death Bloomberg June 17 (Bloomberg) -- Bristol-Myers Squibb Co. and Elan Corp.'s antibiotic Maxipime isn't linked to a higher rate of deaths compared with ... FDA Completes Maxipime Review; Sees No Death RiskNASDAQ US FDA: No higher deaths with Bristol, Elan drugguardian.co.uk (marketed as Maxipime) Update of Ongoing Safety ReviewPharmaLive.com (press release) FiercePharma -AboutLawsuits.com -Attorney at Law all 18 news articles »

BBC News

Medarex shares up as prostate cancer drug shows promise Reuters Ipilimumab is an antibody that is being developed by the company with Bristol-Myers Squibb Co (BMY.N) and is in trials for melanoma, lung cancer and ... Medarex (MEDX) Higher After Experimental Drug Shows Dramatic ResultsStreetInsider.com (subscription) Medarex Surges On Successful Treatment Of Two Cancer PatientsWall Street Journal Medarex's Vaccine-Like Prostate Cancer Treatment Shows Great PromiseSeeking Alpha istockAnalyst.com (press release) all 176 news articles »

GSK further extends its product portfolio in the Middle East and ... PharmiWeb.com (press release) GlaxoSmithKline plc (GSK) today announced that it has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, ... and more »

Bristol Myers (BMY) PriceWatch Alert Technicals Showing Bullish Market Intelligence Center Bristol Myers (NYSE: BMY) ended the last trading session at $20.96. So far the stock has hit a 52-week low of $16.00 and 52-week high of $23.98. ... and more »

Medscape

Stimulant Use Linked to Sudden Death in Pediatric Patients Medscape Received grants for clinical research from: Abbott Laboratories; Addrenex Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb ... and more »

Bristol-Myers Squibb Declares Dividend Trading Markets (press release) Jun 14, 2009 (Close-Up Media via COMTEX) -- BMY | Quote | Chart | News | PowerRating -- The Board of Directors of Bristol-Myers Squibb Company has declared ... Arthritis drug is 'safe in the long term'Hays Pharma all 2 news articles »

Bristol-Myers says ORENCIA demonstrates consistent safety and ... RTT News (RTTNews) - Bristol-Myers Squibb Co (BMY: News ) revealed results of two ORENCIA studies. The first, a long-term extension, or LTE, study, ... Bristol-Myers Says Anti-rheumatic Drug Orencia Shows Consistent ...RTT News all 11 news articles »

Healthcare: Branded Pharma Out, Diagnostics/Generics In Seeking Alpha For the moment I'm still holding on to the Bristol Myers Squibb (BMY) position, as the valuation and yield are even more compelling than Pfizer was at the ... and more »

Squeezing Blood From a Half-Dollar Motley Fool After months of soap-opera rumors, including potential deals with Pfizer (NYSE: PFE), Lundbeck, Bristol-Myers Squibb (NYSE: BMY), and Novartis (NYSE: NVS), ... and more »

Another Day, Another Rumored Suitor Motley Fool So far we've had rumors that Pfizer (NYSE: PFE) and Danish Lundbeck would buy the entire thing and that Bristol-Myers Squibb (NYSE: BMY) would take a ... Novartis in Talks For Parts of ElanTheStreet.com Novartis in talks to buy much of Elan: reportReuters Canada all 60 news articles »

Schaeffer's Daily Option Blog Schaeffers Research Bristol-Myers Squibb (BMY: sentiment, chart, options) may have been the focus of a short straddle on Tuesday. According to data from WhatsTrading.com, ... and more »

Campbell Alliance adds top execs, 7th practice area Bizjournals.com His career has featured stints at GlaxoSmithKline (NYSE: GSK), Bristol Myers Squibb (NYSE: BMY) and Novartis' Sandoz Pharmaceuticals. ... and more »